Please login to the form below

Not currently logged in
Email:
Password:

Gilead EVP, Kevin Young, receives CBE

Kevin Young, executive vice president, Gilead Sciences has been awarded a CBE

Kevin Young, executive vice president, Gilead Sciences has been awarded a CBE "for services to the healthcare and pharmaceutical industries particularly to the development and marketing of life-changing medicines."
 
Young, originally from the north of England, is based at Gilead Sciences in California. Gilead provides the most frequently chosen antiretroviral medicines for the treatment of HIV in the developed world – the life-changing medicines referred to in the CBE citation.

Kevin Young, EVP Gilead Sciences
Kevin Young, EVP Gilead Sciences

 
Gilead's International Access Operations provide these medicines at a no-profit price to almost 100 low-income countries and at sharply discounted prices in a total of 130 developing countries. In total, 2.1 million people worldwide receive one of Gilead's HIV treatments, two thirds (1.4 million) are in the developing world. 

In the UK and Europe, Gilead is well known for Atripla (efavirenz tenofovir emtricitabine): its single tablet regimen (STR) for the treatment of HIV. Atripla is the only single tablet taken once a day that contains the triple-therapy required to successfully control the HIV virus and prevent progression to AIDS.  

13th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics